Copyright © 2006 American Medical Association. All rights reserved.

Slides:



Advertisements
Similar presentations
1 Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT) Jaffe GJ, Martin DF, Toth CA, Daniel.
Advertisements

Phase IIIb Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration PIER Study Year 1 Regillo CD,
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: AMD in the Age-Related Eye Disease Study Chew EY, Clemons TE, Agrón E, et al;
OPHTHALMOLOGY MACULA DEGENERATION MBChB 4 Prof P Roux 2012.
Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized, Placebo-Controlled, Clinical Trial.
Date of download: 5/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Correlation of Increased Vascular Endothelial Growth.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genetic Risk of Primary Open-angle Glaucoma: Population-Based.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Treatment With 9-cis β-Carotene–Rich Powder in Patients.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Solitary Idiopathic Choroiditis: The Richard B. Weaver.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Single-Nucleotide Polymorphisms and Age-Related Macular Degeneration Maguire MG,
Date of download: 6/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Randomized Trial to Evaluate the Efficacy of Cognitive.
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Halo Nevus of the Choroid in 150 Patients: The 2010.
Date of download: 6/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Leopard-Spot Pattern of Yellowish Subretinal Deposits.
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Characteristics of Peripapillary Detachment in Pathologic.
Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Randomized, Placebo-Controlled, Clinical Trial of.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective Trial of Infliximab Therapy for Refractory.
Date of download: 7/9/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Assessment of Multifocal Electroretinogram Abnormalities.
Date of download: 7/14/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Clinical Relevance of Different IgG and IgM Serum.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Projection of Diabetic Retinopathy and Other Major.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Quality of Vision in Patients With Fuchs Endothelial.
Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of Neovascularization but Not Fibrosis.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
Invest. Ophthalmol. Vis. Sci ;48(10): doi: /iovs Figure Legend:
Copyright © 2003 American Medical Association. All rights reserved.
From: Increased Choroidal Neovascularization following Laser Induction in Mice Lacking Lysyl Oxidase-like 1 Invest. Ophthalmol. Vis. Sci ;49(6):
From: Reliability of the Mouse Model of Choroidal Neovascularization Induced by Laser Photocoagulation Invest. Ophthalmol. Vis. Sci ;55(10):
Volume 124, Issue 2, Pages (February 2017)
Copyright © 2012 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Figure Legend: From: Simultaneous OCT/SLO/ICG Imaging
From: Association of Connective Tissue Growth Factor With Fibrosis in Vitreoretinal Disorders in the Human Eye Arch Ophthalmol. 2006;124(10):
Copyright © 2009 American Medical Association. All rights reserved.
From: Holistic integration of gaze cues in visual face and body perception: Evidence from the composite design Journal of Vision. 2017;17(1):24. doi: /
From: Estimating the Yearly Number of Eyes with Treatable Neovascular Age-Related Macular Degeneration Using a Direct Standardization Method and a Markov.
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Invest. Ophthalmol. Vis. Sci ;48(10): doi: /iovs Figure Legend:
Copyright © 2013 American Medical Association. All rights reserved.
Copyright © 2008 American Medical Association. All rights reserved.
Copyright © 2002 American Medical Association. All rights reserved.
From: The Charles Bonnet Syndrome in Patients With Neovascular Age-Related Macular Degeneration: Association With Proton Pump Inhibitors Invest. Ophthalmol.
Copyright © 2006 American Medical Association. All rights reserved.
From: Bone Marrow Transplantation Transfers Age-Related Susceptibility to Neovascular Remodeling in Murine Laser-Induced Choroidal Neovascularization Invest.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2008 American Medical Association. All rights reserved.
From: Choroidal Thickness, Vascular Hyperpermeability, and Complement Factor H in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy.
Copyright © 2000 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
Copyright © 2013 American Medical Association. All rights reserved.
Copyright © 2005 American Medical Association. All rights reserved.
From: Choroidal Blood Flow Response to Isometric Exercise in Glaucoma Patients and Patients with Ocular Hypertension Invest. Ophthalmol. Vis. Sci ;52(10):
Copyright © 2001 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Copyright © 2009 American Medical Association. All rights reserved.
From: Visual Acuities “Hand Motion” and “Counting Fingers” Can Be Quantified with the Freiburg Visual Acuity Test Invest. Ophthalmol. Vis. Sci ;47(3):
Copyright © 2003 American Medical Association. All rights reserved.
From: Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements Trans.
AGE-RELATED MACULAR DEGENERATION (AMD)
Choroidal neovascularization
Copyright © 2008 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
From: Perception of Haidinger Brushes in Macular Disease Depends on Macular Pigment Density and Visual Acuity Invest. Ophthalmol. Vis. Sci ;57(3):
Copyright © 2009 American Medical Association. All rights reserved.
Copyright © 2006 American Medical Association. All rights reserved.
Copyright © 1999 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Choroidal Neovascular
Late fluorescein angiograms of the right macula taken at 13 minutes.
A presentation to: Meeting name Date
Presentation transcript:

Copyright © 2006 American Medical Association. All rights reserved. From: Occult With No Classic Subfoveal Choroidal Neovascular Lesions in Age-Related Macular DegenerationClinically Relevant Natural History Information in Larger Lesions With Good Vision From the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4 Arch Ophthalmol. 2006;124(5):660-664. doi:10.1001/archopht.124.5.660 Figure Legend: Flow diagram for 89 occult with no classic lesions assigned to the placebo group in the Verteporfin in Photodynamic Therapy Trial stratified by baseline visual acuity, with subsequent outcomes by conversion to predominantly classic lesions (area of classic CNV ≥50% of the entire lesion area). For lesions that did not convert to a predominantly classic lesion, subsequent outcomes judged to be clinically relevant for lesions that developed lower levels of visual acuity (approximate Snellen equivalent, ≤20/50−1) are shown. CNV indicates choroidal neovascularization; Minimally classic CNV, an area of classic CNV >0% but <50% of the entire lesion; MPS indicates Macular Photocoagulation Study; and DA, disc areas. Date of download: 11/15/2017 Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved. From: Occult With No Classic Subfoveal Choroidal Neovascular Lesions in Age-Related Macular DegenerationClinically Relevant Natural History Information in Larger Lesions With Good Vision From the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4 Arch Ophthalmol. 2006;124(5):660-664. doi:10.1001/archopht.124.5.660 Figure Legend: Number of eyes with occult with no classic lesions at baseline that converted to minimally classic (area of classic CNV >0% but <50% of the entire lesion) or predominantly classic (area of classic CNV ≥50% of the entire lesion area) lesions by the 12-month or 24-month follow-up examination. Date of download: 11/15/2017 Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved. From: Occult With No Classic Subfoveal Choroidal Neovascular Lesions in Age-Related Macular DegenerationClinically Relevant Natural History Information in Larger Lesions With Good Vision From the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4 Arch Ophthalmol. 2006;124(5):660-664. doi:10.1001/archopht.124.5.660 Figure Legend: Late-phase fluorescein angiogram of a study participant judged to have an occult with no classic lesion (>4 disc areas) at baseline (A) with a visual acuity (approximate Snellen equivalent) of 20/50 or higher. Database information at the 6-month examination indicates evidence of classic choroidal neovascularization (CNV). Subsequent grading of lesion composition of the fluorescein angiogram at the 6-month examination (B) indicates a minimally classic lesion (very bright area of fluorescence in the superotemporal portion of the lesion within a larger area of occult CNV) in which the area of classic CNV is less than 50% of the entire lesion (>4 disc areas), with a visual acuity of 20/63−2. Date of download: 11/15/2017 Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2006 American Medical Association. All rights reserved. From: Occult With No Classic Subfoveal Choroidal Neovascular Lesions in Age-Related Macular DegenerationClinically Relevant Natural History Information in Larger Lesions With Good Vision From the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4 Arch Ophthalmol. 2006;124(5):660-664. doi:10.1001/archopht.124.5.660 Figure Legend: Late-phase fluorescein angiogram of a study participant judged to have an occult with no classic lesion (≤ 4 disc areas) at baseline (A) with a visual acuity (approximate Snellen equivalent) of 20/50+2. The bright area of fluorescence in the center of the lesion was judged to be due to atrophy of the retinal pigment epithelium overlying the occult choroidal neovascularization (CNV) and not classic CNV when the entire fluorescein angiogram was reviewed stereoscopically. Database information at the 12-month examination indicates evidence of classic CNV. Subsequent grading of lesion composition at the 12-month examination (B) indicates conversion to a predominantly classic lesion (≤ 9 disc areas) in which the area of classic CNV is at least 50% of the entire lesion, surrounded by a smaller area of occult CNV, with a visual acuity of 20/200−2. Date of download: 11/15/2017 Copyright © 2006 American Medical Association. All rights reserved.